Recombinant multi-species PARK2/Parkin/PRKN protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PARK2/Parkin/PRKN protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq, Jul 2008]
The Alternative Names of target: AR-JP,E3 ubiquitin-protein ligase parkin,LPRS2,PARK2,PDJ,PRKN,Park,Park2,Parkin,Parkin RBR E3 ubiquitin-protein ligase,Parkinson juvenile disease protein 2 (Parkinson disease protein 2),Prkn

Target products collectionGo to PARK2/Parkin/PRKN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP9203-Ag-1/ GM-Tg-hg-IP9203-Ag-2 Human PARK2/Parkin/PRKN protein Human
GM-Tg-rg-IP9203-Ag-1/ GM-Tg-rg-IP9203-Ag-2 Rat PARK2/Parkin/PRKN protein Rat
GM-Tg-mg-IP9203-Ag-1/ GM-Tg-mg-IP9203-Ag-2 Mouse PARK2/Parkin/PRKN protein Mouse
GM-Tg-cynog-IP9203-Ag-1/ GM-Tg-cynog-IP9203-Ag-2 Cynomolgus/Rhesus macaque PARK2/Parkin/PRKN protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP9203-Ag-1/ GM-Tg-felg-IP9203-Ag-2 Feline PARK2/Parkin/PRKN protein Feline
GM-Tg-cang-IP9203-Ag-1/ GM-Tg-cang-IP9203-Ag-2 Canine PARK2/Parkin/PRKN protein Canine
GM-Tg-bovg-IP9203-Ag-1/ GM-Tg-bovg-IP9203-Ag-2 Bovine PARK2/Parkin/PRKN protein Bovine
GM-Tg-equg-IP9203-Ag-1/ GM-Tg-equg-IP9203-Ag-2 Equine PARK2/Parkin/PRKN protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP9203-Ag-1/ GM-Tg-hg-IP9203-Ag-2; GM-Tg-rg-IP9203-Ag-1/ GM-Tg-rg-IP9203-Ag-2;
GM-Tg-mg-IP9203-Ag-1/ GM-Tg-mg-IP9203-Ag-2; GM-Tg-cynog-IP9203-Ag-1/ GM-Tg-cynog-IP9203-Ag-2;
GM-Tg-felg-IP9203-Ag-1/ GM-Tg-felg-IP9203-Ag-2; GM-Tg-cang-IP9203-Ag-1/ GM-Tg-cang-IP9203-Ag-2;
GM-Tg-bovg-IP9203-Ag-1/ GM-Tg-bovg-IP9203-Ag-2; GM-Tg-equg-IP9203-Ag-1/ GM-Tg-equg-IP9203-Ag-2
Products Name PARK2/Parkin/PRKN protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name PARK2/Parkin/PRKN
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PARK2/Parkin/PRKN protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.